Patrick Campbell is the managing editor of HCPLive. Formerly the editorial lead of Endocrinology Network, Practical Cardiology, and Rheumatology Network, Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. He now helps to lead coverage in each of these respective areas for HCPLive. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter with the Pocono Record in Stroudsburg, PA, and Star News Group in Manasquan, NJ. He also touts experience in multimedia, having spent time as a multimedia specialist with NJ Advance Media and multimedia coordinator at the Pocono Record. Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.
Licogliflozin, a Dual SGLT1/2 Inhibitor, Shows Potential as Treatment for Polycystic Ovary Syndrome
July 19th 2021Data from a phase 2 study of women with overweight or obesity and polycystic ovary syndrome suggests use of licogliflozin was associated with significant reductions in hyperinsulinemia and androgenemia in this patient population.
Read More
Abelacimab Demonstrates Potential of Factor XI Inhibition in Preventing Blood Clots
July 19th 2021A 412-patient trial comparing 3 dosing regimens of abelacimab versus enoxaparin, results indicate all 3 regimens of abelacimab demonstrated noninferiority against enoxaparin and 2 of the 3 demonstrated superiority against the current standard of care.
Read More
FDA Panel Votes Against Roxadustat, Cites Risk of Thrombotic Events
July 16th 2021The subject of a July 15 meeting, the FDA's Cardiovascular and Renal Drugs Advisory Committee voted 13-1 and 12-2 against recommending approval of roxadustat for treatment of anemia in adult patients with chronic kidney disease not on dialysis and on dialysis, respectively.
Read More
Methamphetamine-Associated Heart Failure Placing Major Burden on California Health Care Systems
July 15th 2021From 2008 to 2018, the rate of methamphetamine-associated heart failure hospitalizations in California has risen by nearly 600% while the costs associated with these events has risen by more than 800% during that same time frame.
Read More
Regular Antidepressant Use Linked to Improved Outcomes In Patients with Diabetes and Depression
July 15th 2021Analysis of more than 35,000 patients with diabetes and depressive disorder indicates patients with greater adherence to antidepressants appeared to experience fewer complications and a lower rate of mortality than those with suboptimal use.
Read More
An analysis of data from the Framingham Heart Study Offspring Cohort by investigators at the USDA Human Nutrition Research Center on Aging suggests greater consumption of whole grains was associated with a more preferable cardiometabolic risk profile than lesser consumption or consumption of refined grains.
Read More
Testosterone Therapy Could Improve Cardiovascular Health in Men with Hypogonadism
July 13th 2021A study from the Annual Congress of the European Association of Urology suggests undergoing testosterone therapy could improve cardiovascular health and reduce risk of adverse events in men with hypogonadism.
Read More
Leading Cardiology Organizations Publish Joint Opinion on Clinician Well-Being
July 13th 2021Four of the world's leading cardiology organizations—the ESC, ACC, AHA, and WHF—have collaborated to form a joint opinion statement seeking to address and outline drivers and strategies for mitigation of burnout.
Read More
Finerenone (KERENDIA) Approved for Chronic Kidney Disease Associated with Type 2 Diabetes
July 9th 2021With approval on July 9, finerenone (Kerendia) becomes the first nonsteroidal mineralocorticoid receptor antagonist to receive approval for use in adults with chronic kidney disease associated with type 2 diabetes.
Read More
EMPEROR-Preserved Meets Primary Endpoint, Cements Empagliflozin's Potential in HFpEF
July 6th 2021While many have speculated about the effect of SGLT2 inhibitors in HFpEF for years, EMPEROR-Preserved provides the first evidence from a phase 3 RCT of the safety and efficacy of empagliflozin for use in patients with heart failure across the spectrum of ejection fraction.
Read More
ADA 2021: Tirzepatide Demonstrates Potential in Type 2 Diabetes with SURPASS Trials
June 29th 2021Data from the SURPASS program presented at ADA 2021 provide insight into the effects of tirzepatide on HbA1c control and body weight in a variety of different patient populations as both an add-on and monotherapy.
Read More
ADA 2021: Sotagliflozin Impact in Patients with Type 2 Diabetes Highlighted in Special Session
June 29th 2021While still waiting for regulatory approval, the SCORED and SOLOIST trial have demonstrated the impact of sotagliflozin, a dual SGLT1/2 inhibitor, on patients with type 2 diabetes and chronic kidney disease or heart failure.
Read More
Adding Finerenone to SGLT2 Inhibitor Could Boost Renoprotective Benefit in Patients with Diabetes
June 29th 2021An analysis from ADA 2021 suggests the renoprotective benefits of finerenone were consistent irrespective of SGLT2 inhibitor use and those using an SGLT2 inhibitor with finerenone resulted in greater UACR reductions.
Read More
AMPLITUDE-O: Efpeglenatide Shows Promise for Reducing CV, Kidney Events in Patients with Diabetes
June 28th 2021Data from the AMPLITUDE-O trial demonstrates the effects of the exendin-4-based GLP-1 RA efpeglenatide on cardiovascular and renal outcomes among patients with type 2 diabetes and cardiovascular disease or kidney disease.
Read More
Semaglutide 2.0 mg Proves Superiority vs Ozempic for Glycemic Control, Weight Loss in SUSTAIN FORTE
June 28th 2021A pair of studies presented at ADA 2021 detail the effects of an investigational 2.0 mg dose of semaglutide compared to semaglutide 1.0 mg (Ozempic) on glycemic control and body weight in patients with type 2 diabetes in SUSTAIN FORTE.
Read More
SENZA-PDN: High-Frequency Spinal Cord Stimulation Provides Durable Pain Relief Out to 12 Months
June 27th 2021Data from a RCT demonstrate the impact of high-frequency spinal cord stimulation on pain and quality of life among patients with a history of painful diabetic neuropathy lasting more than a year.
Read More
T1D Exchange Registry Data Provides Insight into Current Trends of Management in Type 1 Diabetes
June 27th 2021Research from the T1D Exchange Registry paints a picture describing current trends in the management of diabetes among patients with type 1 diabetes enrolled within the online registry.
Read More
Background Insulin Use Does Not Impact Benefits of Finerenone in Diabetic Kidney Disease
June 27th 2021An analysis of FIDELIO-DKD demonstrates the benefits of finerenone use was consistent regardless of baseline insulin use among patients with type 2 diabetes and CKD included in the phase 3 trial.
Read More
Real-Time CGM Use Associated with Reduced Medical Costs in Patients with Type 2 Diabetes
June 27th 2021A look at the medical spending of more than 500 patients with type 2 diabetes who initiated therapy with real-time continuous glucose monitoring details the reductions in medical costs associated with initiation of real-time CGM.
Read More
ADA 2021 Study Outlines Benefits of RPM on Glycemic Control in Patients with Type 2 Diabetes
June 26th 2021A study assessing use of remote patient monitoring in patients with type 2 diabetes outlines the impact continued participation in digital monitoring programs can have on glycemic control among this patient population.
Read More
Finerenone Provides Consistent Benefit, Irrespective of Background GLP-1 RA Use
June 26th 2021A FIDELIO-DKD analysis presented at ADA 2021 suggests the renal and cardiovascular benefits of finerenone were consistent, irrespective of background GLP-1 RA use and indicate the presence of both was associated with even greater reductions in albuminuria.
Read More